Browsing articles from "September, 2021"

Failure to diagnose Giant Cell Arteritis results in settlement

OMIC has seen several sizeable settlements resulting from failure to diagnose giant cell arteritis cases in the past few years. In 2020, alone, there were two large settlements, this one for $475K and another case for $600K. The settlements are large because GCA, if diagnosis does not occur or is delayed, often leads to bilateral blindness in elderly patients. 

Allegation: Failure to diagnose giant cell arteritis in a 79-year-old. 

Disposition: Settlement of $475K. 

Read the entire treatment history, analyses, and takeaways from these two claims on pg. 6 of the 2022 Digest Vol 32 N0 1.

2022 Digest (Vol 32 No 1)

Allegations of failure to diagnose are common in medical malpractice lawsuits against ophthalmologists, and diagnostic error is an issue of ongoing concern in the healthcare community. In fact, one of the “Top 10 Patient Safety Concerns” listed in an ECRI (formerly the Emergency Care Research Institute) and Institute for Safe Medication Practices (ISMP) 2022 special report is “Cognitive Biases and Diagnostic Error.” We examine solutions. 

Read more…

(some links within this PDF document may not work in all browsers due to security controls or other reasons. To correct this issue, the document may be downloaded and then the links should work, or copied from the document directly into a new window in your browser)

Pages:«12




Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.

61864684